Table Info

Table 1.

Approved CAR-T cell therapies

Trade name (generic name)	Target	Indication	Approval year	Company	Clinical study
Kymriah (tisagenlecleucel)	CD19	Patients under the age of 25 with B-cell ALL that is refractory or in second or subsequent relapse	2017	Novartis	ELIANA trial [3]
		Adults with R/R LBCL after two or more lines of systemic therapy (including DLBCL-NOS, HGBCL, and DLBCL arising from FL)	2018		JULIET trial [4]
		Adults with R/R FL after two or more lines of systemic therapy	2022		ELARA trial [5]
Yescarta (axicabtagene ciloleucel)	CD19	Adults with R/R LBCL (including PMBCL, HGBCL, and DLBCL arising from FL) after two or more lines of systemic therapy	2017	Gilead Sciences	ZUMA-1 trial [6]
		Adults with R/R FL after two or more lines of systemic therapy	2021		ZUMA-5 trial [7]
		Patients with R/R LBCL and within a maximum of 12 months following first-line chemoimmunotherapy	2022		ZUMA-7 trial [8]
Tecartus (brexucabtagene autoleucel)	CD19	Adults with R/R mantle cell lymphoma	2020	Gilead Sciences	ZUMA-2 trial [9]
Tecartus (brexucabtagene autoleucel)	CD19	Adult patients with R/R B-cell precursor ALL	2021	Gilead Sciences	ZUMA-3 trial [10]
Breyanzi (lisocabtagene maraleucel)	CD19	Adults with R/R LBCL who have previously received 2 or more systemic therapies	2021	Bristol Myers Squibb	TRANSCEND NHL 001 trial [11]
		Adults with R/R LBCL: Refractory to first-line chemoimmunotherapy Relapse within 12 months after first-line chemoimmunotherapy	2022		TRANSFORM trial [12]
		Adults with R/R CLL and SLL, who have received at least 2 prior therapies, including a BTK inhibitor and B-cell lymphoma 2 inhibitor venetoclax	2024		TRANSCEND CLL 004 trial [13]
Carteyva (relmacabtagene autoleucel)	CD19	Adults with R/R LBCL after two or more lines of systemic therapy	2021	JW Therapeutics	RELIANCE trial [14]
Abecma (idecabtagene vicleucel)	BCMA	Patients with R/R multiple myeloma after three or more previous lines of therapy including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody	2021	Bristol Myers Squibb	KarMMa trial [15]
Carvykti (ciltacabtagene autoleucel)	BCMA	Patients with multiple myeloma: After three or more previous lines of therapy Double-refractory to a proteasome inhibitor and an immunomodulatory drug, and had received a proteasome inhibitor, immunomodulatory agent, and anti-CD38 antibody	2022	Janssen Pharmaceuticals	CARTITUDE-1 trial [16]
ARI-0001	CD19	Patients aged > 25 years with R/R ALL	2021	Hospital Clinic of Barcelona	CART19-BE-01 trial [17]

ALL: acute lymphoblastic leukemia; BCMA: B-cell maturation antigen; BTK: Bruton tyrosine kinase; CAR: chimeric antigen receptor; CLL: chronic lymphocytic leukemia; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; HGBCL: high-grade B-cell lymphoma; LBCL: large B-cell lymphoma; NOS: not otherwise specified; PMBCL: primary mediastinal B-cell lymphoma; R/R: recurrent/refractory; SLL: small lymphocytic lymphoma

Declarations

Author contributions

RM: Conceptualization, Writing—original draft, Supervision. RK: Writing—original draft. MF and VC: Visualization. EB: Writing—review & editing, Funding acquisition. All authors have read and agreed to the published version of the manuscript.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This study was funded by Russian Science Foundation (RSF) grant [22-74-10076] to EB in the decision to submit the paper for publication. This work has been supported by the Kazan Federal University Strategic Academic Leadership Program [PRIORITY-2030]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Giorgioni L, Ambrosone A, Cometa MF, Salvati AL, Magrelli A. CAR-T State of the Art and Future Challenges, A Regulatory Perspective. Int J Mol Sci. 2023;24:11803. [DOI] [PubMed] [PMC]

Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69. [DOI] [PubMed] [PMC]

Laetsch TW, Myers GD, Baruchel A, Dietz AC, Pulsipher MA, Bittencourt H, et al. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. Lancet Oncol. 2019;20:1710–8. [DOI] [PubMed] [PMC]

Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al.; JULIET Investigators. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380:45–56. [DOI] [PubMed]

Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28:325–32. [DOI] [PubMed]

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377:2531–44. [DOI] [PubMed] [PMC]

Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23:91–103. [DOI] [PubMed]

Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al.; All ZUMA-7 Investigators and Contributing Kite Members. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022;386:640–54. [DOI] [PubMed]

Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020;382:1331–42. [DOI] [PubMed] [PMC]

10.

Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398:491–502. [DOI] [PubMed]

11.

Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839–52. [DOI] [PubMed]

12.

Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al.; TRANSFORM Investigators. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399:2294–308. [DOI] [PubMed]

13.

Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, et al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study. Lancet. 2023;402:641–54. [DOI] [PubMed]

14.

Zhu J, Ying Z, Song Y, Yang H, Guo Y, Li W, et al. Clinical Response of CD19 CAR-T Cells (relmacabtagene autoleucel, relma-cel) in Adults with Heavily-Pre-Treated Relapsed/Refractory (r/r) Large B-Cell Lymphoma in China. Blood. 2020;136:39–40. [DOI]

15.

Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384:705–16. [DOI] [PubMed]

16.

Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398:314–24. [DOI] [PubMed]

17.

Ortiz-Maldonado V, Frigola G, Español-Rego M, Balagué O, Martínez-Cibrián N, Magnano L, et al. Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter’s Transformation. Front Oncol. 2022;12:828471. [DOI] [PubMed] [PMC]

18.

Mancikova V, Peschelova H, Kozlova V, Ledererova A, Ladungova A, Verner J, et al. Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia. J Immunother Cancer. 2020;8:e000471. [DOI] [PubMed] [PMC]

19.

Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Döhner K, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123:3247–54. [DOI] [PubMed]

20.

Zenz T, Eichhorst B, Busch R, Denzel T, Häbe S, Winkler D, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28:4473–9. [DOI] [PubMed]

21.

Gonzalez D, Martinez P, Wade R, Hockley S, Oscier D, Matutes E, et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol. 2011;29:2223–9. [DOI] [PubMed]

22.

De Marco RC, Monzo HJ, Ojala PM. CAR T Cell Therapy: A Versatile Living Drug. Int J Mol Sci. 2023;24:6300. [DOI] [PubMed] [PMC]

23.

Ma Q, Garber HR, Lu S, He H, Tallis E, Ding X, et al. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells. Cytotherapy. 2016;18:985–994. [DOI] [PubMed] [PMC]

24.

Ramachandran I, Lowther DE, Dryer-Minnerly R, Wang R, Fayngerts S, Nunez D, et al. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. J Immunother Cancer. 2019;7:276. [DOI] [PubMed] [PMC]

25.

Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature. 2023;614:635–48. [DOI] [PubMed]

26.

Cho JH, Collins JJ, Wong WW. Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses. Cell. 2018;173:1426–38.e11. [DOI] [PubMed] [PMC]

27.

Urbanska K, Lanitis E, Poussin M, Lynn RC, Gavin BP, Kelderman S, et al. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res. 2012;72:1844–52. [DOI] [PubMed] [PMC]

28.

Yan T, Zhu L, Chen J. Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Exp Hematol Oncol. 2023;12:14. [DOI] [PubMed] [PMC]

29.

Valkenburg KC, de Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol. 2018;15:366–81. [DOI] [PubMed] [PMC]

30.

Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee CC, Restifo NP, et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med. 2013;210:1125–35. [DOI] [PubMed] [PMC]

31.

Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, et al. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017;3:1094–101. [DOI] [PubMed] [PMC]

32.

Goff SL, Morgan RA, Yang JC, Sherry RM, Robbins PF, Restifo NP, et al. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma. J Immunother. 2019;42:126–35. [DOI] [PubMed] [PMC]

33.

Liu Z, Zhou J, Yang X, Liu Y, Zou C, Lv W, et al. Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma. Mol Cancer. 2023;22:3. [DOI] [PubMed] [PMC]

34.

Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, et al. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. J Clin Invest. 2016;126:3036–52. [DOI] [PubMed] [PMC]

35.

Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang WC, et al. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8⁺ T Cells in Patients with Recurrent Glioblastoma. Clin Cancer Res. 2015;21:4062–72. [DOI] [PubMed] [PMC]

36.

Zhang G, Zhao Y, Liu Z, Liu W, Wu H, Wang X, et al. GD2 CAR-T cells in combination with Nivolumab exhibit enhanced antitumor efficacy. Transl Oncol. 2023;32:101663. [DOI] [PubMed] [PMC]

37.

Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24:739–48. [DOI] [PubMed]

38.

Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25:625–38. [DOI] [PubMed]

39.

Allen GM, Frankel NW, Reddy NR, Bhargava HK, Yoshida MA, Stark SR, et al. Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science. 2022;378:eaba1624. [DOI] [PubMed] [PMC]

40.

Lozano G, Levine AJ, editors. The p53 Protein: From Cell Regulation to Cancer. Cold Spring Harbor Laboratory Press; 2016.

41.

Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502:333–9. [DOI] [PubMed] [PMC]

42.

Mantovani F, Walerych D, Sal GD. Targeting mutant p53 in cancer: a long road to precision therapy. FEBS J. 2017;284:837–50. [DOI] [PubMed]

43.

Kim MP, Lozano G. Mutant p53 partners in crime. Cell Death Differ. 2018;25:161–8. [DOI] [PubMed] [PMC]

44.

Walerych D, Napoli M, Collavin L, Del Sal G. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis. 2012;33:2007–17. [DOI] [PubMed] [PMC]

45.

Walerych D, Lisek K, Del Sal G. Mutant p53: One, No One, and One Hundred Thousand. Front Oncol. 2015;5:289. [DOI] [PubMed] [PMC]

46.

Raja DS, Paramaguru G, Bhuvanesh NS, Reibenspies JH, Renganathan R, Natarajan K. Effect of terminal N-substitution in 2-oxo-1,2-dihydroquinoline-3-carbaldehyde thiosemicarbazones on the mode of coordination, structure, interaction with protein, radical scavenging and cytotoxic activity of copper(II) complexes. Dalton Trans. 2011;40:4548–59. [DOI] [PubMed]

47.

Vogiatzi F, Brandt DT, Schneikert J, Fuchs J, Grikscheit K, Wanzel M, et al. Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5. Proc Natl Acad Sci U S A. 2016;113:E8433–42. [DOI] [PubMed] [PMC]

48.

Walerych D, Lisek K, Sommaggio R, Piazza S, Ciani Y, Dalla E, et al. Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. Nat Cell Biol. 2016;18:897–909. [DOI] [PubMed]

49.

Rodriguez OC, Choudhury S, Kolukula V, Vietsch EE, Catania J, Preet A, et al. Dietary downregulation of mutant p53 levels via glucose restriction. Cell Cycle. 2012;11:4436–46. [DOI] [PubMed] [PMC]

50.

Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell. 2003;3:387–402. [DOI] [PubMed]

51.

Zhang C, Liu J, Liang Y, Wu R, Zhao Y, Hong X, et al. Tumour-associated mutant p53 drives the Warburg effect. Nat Commun. 2013;4:2935. [DOI] [PubMed] [PMC]

52.

Fontemaggi G, Dell’Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F, et al. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol. 2009;16:1086–93. [DOI] [PubMed]

53.

Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, et al. Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell. 2013;23:634–46. [DOI] [PubMed] [PMC]

54.

Yeudall WA, Vaughan CA, Miyazaki H, Ramamoorthy M, Choi MY, Chapman CG, et al. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. Carcinogenesis. 2012;33:442–51. [DOI] [PubMed]

55.

Cooks T, Pateras IS, Jenkins LM, Patel KM, Robles AI, Morris J, et al. Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246. Nat Commun. 2018;9:771. [DOI] [PubMed] [PMC]

56.

Blagih J, Buck MD, Vousden KH. p53, cancer and the immune response. J Cell Sci. 2020;133:jcs237453. [DOI] [PubMed]

57.

Ghosh M, Saha S, Bettke J, Nagar R, Parrales A, Iwakuma T, et al. Mutant p53 suppresses innate immune signaling to promote tumorigenesis. Cancer Cell. 2021;39:494–508.e5. [DOI] [PubMed] [PMC]

58.

Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703–13. [DOI] [PubMed] [PMC]

59.

Robinson DR, Wu YM, Lonigro RJ, Vats P, Cobain E, Everett J, et al. Integrative clinical genomics of metastatic cancer. Nature. 2017;548:297–303. [DOI] [PubMed] [PMC]

60.

Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature. 1992;355:846–7. [DOI]

61.

de Andrade KC, Lee EE, Tookmanian EM, Kesserwan CA, Manfredi JJ, Hatton JN, et al. The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute. Cell Death Differ. 2022;29:1071–3. [DOI] [PubMed] [PMC]

62.

Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, et al. A census of human cancer genes. Nat Rev Cancer. 2004;4:177–83. [DOI] [PubMed] [PMC]

63.

Stracquadanio G, Wang X, Wallace MD, Grawenda AM, Zhang P, Hewitt J, et al. The importance of p53 pathway genetics in inherited and somatic cancer genomes. Nat Rev Cancer. 2016;16:251–65. [DOI] [PubMed] [PMC]

64.

Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;63:1129–36. [DOI] [PubMed]

65.

Mansur MB, deSouza NM, Natrajan R, Abegglen LM, Schiffman JD, Greaves M. Evolutionary determinants of curability in cancer. Nat Ecol Evol. 2023;7:1761–70. [DOI] [PubMed]

66.

Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer. 2005;92:434–44. [DOI] [PubMed] [PMC]

67.

Vousden KH, Lu X. Live or let die: the cell’s response to p53. Nat Rev Cancer. 2002;2:594–604. [DOI] [PubMed]

68.

Vogt U, Zaczek A, Klinke F, Granetzny A, Bielawski K, Falkiewicz B. p53 Gene status in relation to ex vivo chemosensitivity of non-small cell lung cancer. J Cancer Res Clin Oncol. 2002;128:141–7. [DOI] [PubMed]

69.

Higashiyama M, Kodama K, Yokouchi H, Takami K, Doi O, Kobayashi H, et al. Immunohistochemical p53 protein status in nonsmall cell lung cancer is a promising indicator in determining in vitro chemosensitivity to some anticancer drugs. J Surg Oncol. 1998;68:19–24. [DOI] [PubMed]

70.

Gruber M, Wu CJ. Evolving understanding of the CLL genome. Semin Hematol. 2014;51:177–87. [DOI] [PubMed] [PMC]

71.

Roselle C, Horikawa I, Chen L, Kelly AR, Gonzales D, Da T, et al. Enhancing chimeric antigen receptor T cell therapy by modulating the p53 signaling network with Δ133p53α. Proc Natl Acad Sci U S A. 2024;121:e2317735121. [DOI] [PubMed] [PMC]

72.

Horikawa I, Park KY, Isogaya K, Hiyoshi Y, Li H, Anami K, et al. Δ133p53 represses p53-inducible senescence genes and enhances the generation of human induced pluripotent stem cells. Cell Death Differ. 2017;24:1017–28. [DOI] [PubMed] [PMC]

73.

Mancikova V, Smida M. Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia. Int J Mol Sci. 2021;22:5536. [DOI] [PubMed] [PMC]

74.

Shouval R, Alarcon Tomas A, Fein JA, Flynn JR, Markovits E, Mayer S, et al. Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy. J Clin Oncol. 2022;40:369–81. [DOI] [PubMed] [PMC]

75.

Zhang X, Lu XA, Yang J, Zhang G, Li J, Song L, et al. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv. 2020;4:2325–38. [DOI] [PubMed] [PMC]

76.

Porpaczy E, Wohlfarth P, Königsbrügge O, Rabitsch W, Skrabs C, Staber P, et al. Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era. Cancers (Basel). 2021;13:5592. [DOI] [PubMed] [PMC]

77.

Gao F, Hu K, Zheng P, Shi H, Ke X. Characteristics and prognosis of rrDLBCL with TP53 mutations and a high-risk subgroup represented by the co-mutations of DDX3X-TP53. Cancer Med. 2023;12:10267–79. [DOI] [PubMed] [PMC]

78.

Xue B, Liu Y, Zhou J, Zhou L, Ye S, Lu Y, et al. CD19 CAR-T treatment shows limited efficacy in r/r DLBCL with double expression and TP53 alterations. Cytotherapy. 2024;26:1465–71. [DOI] [PubMed]

79.

Eder LN, Martinovic D, Mazzeo P, Ganster C, Hasenkamp J, Thomson J, et al. Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy. Curr Oncol. 2023;30:1146–50. [DOI] [PubMed] [PMC]

80.

Zhang Q, Zhu X, Liu B, Zhang Y, Xiao Y. Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations. Front Immunol. 2023;14:1127868. [DOI] [PubMed] [PMC]

81.

Shouval R, Alarcon Tomas A, Fein JA, Flynn J, Markovits E, Mayer S, et al. TP53 and CD19-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma. Blood. 2021;138:710. [DOI]

82.

Mueller J, Schimmer RR, Koch C, Schneiter F, Fullin J, Lysenko V, et al. Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells. EMBO Mol Med. 2024;16:445–74. [DOI] [PubMed] [PMC]